2026, Number 1
Next >>
Rev Med UAS 2026; 16 (1)
Challenges of personalized medicine in cancer
López-Ceballos AG, Beltrán-Ontiveros SA
Language: Spanish
References: 8
Page: 3-4
PDF size: 105.70 Kb.
Text Extraction
No abstract.
REFERENCES
Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statisticsfor the year 2020: An overview. Int J cancer. 2021 Aug 15;149(4):778-89.
Hernández-Pedro N, Soca-Chafre G, Alaez-Versón C, Carrillo-Sánchez K, Avilés-Salas A, VergaraE, et al. Mutational profile by targeted next generation sequencing of non-small cell lungcancer in the Mexican population. Sal Pub Mex. 2020 Mar 20;61:308-17.
Fernandez-Garza LE, Dominguez-Vigil IG, Garza-Martinez J, Valdez-Aparicio EA, Barrera-BarreraSA, Barrera-Saldana HA. Personalized medicine in ovarian cancer: a perspective fromMexico. W J Oncol. 2021 Jul 10;12(4):85.
Singh D, Dhiman VK, Pandey M, Dhiman VK, Sharma A, Pandey H, et al. Personalized medicine:An alternative for cancer treatment. Canc Treat Res Comm. 2024 Jan 1;42:100860.
Sadee W, Wang D, Hartmann K, Toland AE. Pharmacogenomics: driving personalized medicine.Pharmacol Rev. 2023 Jul 1;75(4):789-814.
Morand S, Devanaboyina M, Staats H, Stanbery L, Nemunaitis J. Ovarian cancer immunotherapyand personalized medicine. Int J Mol Sci. 2021;22(12):6532.
Braig ZV. Personalized medicine: From diagnostic to adaptive. Biomed J. 2022;45:132–142.
Slim MA, van Mourik N, Bakkerus L, Fuller K, Acharya L, Giannidis T, et al. Towards personalizedmedicine: a scoping review of immunotherapy in sepsis. Crit Care. 2024;28:183.
Full text